Methods: The quantities and patterns of oral and parenteral AMU from 2011 to 2013 in Japanese medical institutions in 47-prefecture units were analyzed using NDB collected through the Ministry of Health, Labor and Welfare of Japan, which accounted for 98% of total claim data in Japan. The data were analyzed in accordance with the Anatomical Therapeutic Chemical (ATC) classification using the defined daily dose (DDD) as a measurement unit, as recommended by the WHO Collaborating Centre for Drug Statistics Methodology. The AMU data was normalized and reported as DDDs per 1000 inhabitants in each prefecture per day (DID). Trends of DID from 2011 to 2013 in each prefecture was analyzed and inter-regional comparison was performed.
Results: All prefectures demonstrated increased trends in both oral and parenteral AMU (DID) from 2011 to 2013. The median (max, min) AMU (DID) for oral and parenteral AMUs in 2011, 2012, 2013 were 12.7 (15.3, 10.1), 13.2 (15.9, 10.8), 13.2(15.9, 10.9), and 0.84 (1.04, 0.54), 0.89 (1.05, 0.57), 0.92 (1.11, 0.62), respectively. When the data was analyzed based on dividing Japan into three regions (eastern, central, and western Japan), there were significant geographical difference in both oral and parenteral AMU, with the highest values in the western Japan.
Conclusion: AMU has increased from 2011 and 2013 regardless of the dosage form in all prefectures in Japan. Geographical analysis demonstrated regional distribution of AMU within the country. The NDB can be used as a tool for AMU monitoring to assess regional action to combat against AMR.
D. Yamasaki, None
G. Kato, None
T. Yagi, None